Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial

Journal of Clinical Oncology

Volumn 22, Issue 12, 2004, Pages 2461-2468

  Butler, Lorna ^a   Bacon, Monica ^a   Carey, Mark ^a   Zee, Benny ^a   Tu, Dongsheng ^a   Bezjak, Andrea ^a  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADULT; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGISTRY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG CYTOTOXICITY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INFORMATION RETRIEVAL; LETHARGY; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MEDICAL RECORD; MUSCLE WEAKNESS; NAUSEA; OVARY CARCINOMA; PREDICTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; REGRESSION ANALYSIS; SCORING SYSTEM; MULTICENTER STUDY; OVARY TUMOR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; HUMANS; MATCHED-PAIR ANALYSIS; OVARIAN NEOPLASMS; PACLITAXEL; QUALITY OF LIFE;

EID: 2942709855     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.01.106     Document Type: Article

References (14)

1. Canadian Cancer Statistics 2002: Canadian Cancer Society, National Cancer Institute of Canada, Statistics Canada Provincial/Territorial Cancer Registries and Health Canada. http://www.cancer.ca
2. Brundage MD, Davidson J, Mackillop W: Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol 15:330-340, 1997
3. Calhoun E, Bennett C, Peeples P, et al: Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists. Gynecol Oncol 71:369-375, 1998
4. Montazeri A, McEwen J, Gillis C: Quality of life in patients with ovarian cancer: Current state of research. Support Care Cancer 4:169-179, 1996
5. Machin D, Weeden S: Suggestions for the presentation of quality of life data from clinical trials. Stat Med 17:711-724, 1998
6. Piccart M, Bertelsen K, James K, et al: Randomized intergroup trial of cisplatin-paclitaxed versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 92:699-708, 2000
7. National Cancer Institute of Canada Clinical Trials Group: Expanded Common Toxicity Criteria. Kingston, Ontario, Canada, National Cancer Institute of Canada Clinical Trials Group, 1994, pp 1-35
8. Osoba D, Zee B, Pater J, et al: Psychometric properties and responsiveness of EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 3:353-364, 1994
9. Feinstein A, Cicchetti D: High agreement but low kappa, I: The problems of two paradoxes. J Clin Epidemiol 43:543-549, 1999
10. Cicchetti D, Feinstein A: High agreement but low kappa. II: Resolving the paradoxes. J Clin Epidemiol 43:551-558, 1990
11. MacKinnon A: A spreadsheet for the calculation of comprehensive statistics for the assessment of diagnostic tests and inter-rater agreement. Comput Biol Med 30:127-134, 2000
12. Osoba D, Zee B, Pater J, et al: Determinants of postchemotherapy nausea and vomiting in patients with cancer. J Clin Oncol 15:116-123, 1997
13. Savage C, Pater J, Tu D, et al: He said/she said: How much agreement is there on symptoms between common toxicity criteria and quality of life? Proc Am Soc Clin Oncol 21:386a, 2002 (abstr 1540)
14. Brundage M, Pater J, Zee B: Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. J Natl Cancer Inst 85:1138-1148, 1993